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Abstract:  
The Kingdom of Saudi Arabia (KSA) has a population of 32.6 million in 2018, with a growth 
rate of 2.65% per annum. In “World Health organization’s Ranking, WHO has ranked Saudi 
Arabia at 26 among 191 countries for the performance in overall healthcare and was commended 
as a model for other countries.   The public sector is currently the main provider of healthcare 
and is mainly funded by the government. The government has initiated a process to include the 
private sector by launching the National Transformation Program (NTP) in 2016. The objectives 
of NTP 2020 are to expand the role of the private sector from 25% to 35% by 2020; to increase 
the number of internationally accredited hospitals and to decrease the percentage of smoking and 
obesity by establishing a strategy focused on preventive medicine and advocate for a healthy 
lifestyle and wellness. The country major challenges to healthcare include an aging population, 
sedentary lifestyles, growing demand for healthcare services and changing disease patterns.  This 
article describes the need to build a conceptual model and the future directions for medicines 
policy in the country. The model is needed to narrate and document the set of challenges with 
regards to workforce, professional development, human and health services for the 
pharmaceutical and medicines sector. A conceptual model could aid to build and identify priority 
medicines policy issues. The model describes stakeholders involvement, including government, 
policy makers, industry, academics, and consumers who could be involved in the policy 
development. Interaction between these stakeholders, as well as thematic document 
analysis, could lead to identifying some of the future health and medicines policy challenges in 
the country. There challenges could include the use of new biotechnological products, dose 
tailoring, funding of high cost medicines, accessibility of services and supporting health 
economic and pharmacoinformatics research . 
  
  
 
 
 
 Introduction: 
 
The Kingdom of Saudi Arabia (KSA) has a population of 32.6 million in 2018, with a growth 
rate of 2.65% per annum [1]. This population is expected to increase by 77.2 million by 2050 [2]. 
Saudi Arabia's healthcare system has gone through huge improvements in the last 50 years [3, 4]. 
As a result of modernization, a large network of healthcare facilities including hundreds of 
hospitals and thousands of primary care centers have been established in the country [3, 4]. In 
“World Health organization’s Ranking, WHO has ranked Saudi Arabia at 26 among 191 
countries for the performance in overall healthcare and was commended as a model to other 
countries. It is expected that life expectancy in Saudi Arabia would increase from 73.1 years to 
78.4 for males and 76.1 years to 81.3 for females respectively by 2050 [2]. The country’s major 
mortality indicators are Diabetes (36 %), Ischemic heart diseases(25.4%), Chronic kidney 
diseases (25.1%), and Road accident injuries(32.3%) [5].Morbidity and mortality indicators 
share characteristics with both high-income and low-income countries [6]. 
 
  
Provision of Healthcare in Saudi Arabia 
 
 Healthcare in Saudi Arabia is provided by a three-level system (primary, secondary 
and tertiary healthcare). In 2018, the total healthcare expenditures were 37.7 billion US$ 
[141.375 billion Saudi Riyal]  [5].The public sector is currently the main provider of healthcare 
and is mainly funded by the government [7]. Ministry of Health (MOH) and other government 
sectors such as the Ministry of Defense, Ministry of the Interior, Ministry of Education, and 
Ministry of the National Guard are the major healthcare providers that account for approximately 
80% of the total services provided nationwide [8]. The MOH and other government healthcare 
providers deliver all curative services, including primary, secondary, and tertiary care, 
rehabilitation, home healthcare, and long-term care  [8]. 
 
There is also a Compulsory Employment-Based Health Insurance (CEBHI), in which the 
employer covers the cost of medical care in the private sector. The cooperative health insurance 
coverage includes all individual employees working in the private sector and their families [9]. 
The CEBHI scheme was implemented in Saudi Arabia to benefit expatriate workers in the 
private sector [9,10]. 
 
Education and healthcare spending accounts for the largest share of the Saudi 2018 budget, 
accounting for more than 36% of the total budget [5].Saudi Arabia is considering privatization of 
its health-care services with the goal to improve healthcare access and efficiency [8].In this 
context, the MOH is intending to change its role to form the provider of healthcare facilities to 
the regulator of those services [2]. 
 
 
Public spending accounts for 79% of the total budget, though the government has initiated a 
process to include the private sector by launching the National Transformation Program (NTP) in 
2016. The objectives of NTP 2020 are to expand the role of the private sector from 25% to 35% 
by 2020; to increase the number of internationally accredited hospitals and to decrease the 
percentage of smoking and obesity by establishing a strategy focused on preventive medicine 
and advocate for a healthy lifestyle and wellness [5]. 
 Healthcare Challenges 
 
 The country major challenges to healthcare include an aging population, sedentary lifestyles, 
growing demand for healthcare services and changing disease patterns. There is a change in 
disease patterns from communicable to non-communicable diseases in Saudi Arabia [11]. 
Modern health issues have emerged due to an affluent society, adoption of modern diets and the 
lack of physical activities. Both the prevalence of cardiovascular diseases as well as the share of 
the population with diabetes have increased [1]. Some of the other challenges are poor referral 
systems between primary care centers and hospitals; long waiting time, underutilization of e-
health and information systems and the accessibility of healthcare services in remote regions of 
Saudi Arabia [7,12]. 
 
 Healthcare services and medicines are provided free of charge to all citizens and expatriates 
working in the government sector [13].However, for several reasons (e.g., quality of care, long 
waiting times), it is common for people to seek treatment and medical care at private hospitals 
and polyclinics [7].In some accounts, it's Saudi Arabia success to counter many challenges and 
to increase the quality and quantity of life for its citizens. However, Saudi Arabia is standing at 
the crossroads. Saudi Arabia focuses now to change its economy from wealth generated through 
oil to more technology base and the challenges lay ahead in terms of health, population, and 
public policy. 
 
 
  
Pharmaceuticals in Saudi Arabia 
 
In Saudi Arabia, local pharmaceutical companies produce only approximately 17% of the 
domestic pharmaceuticals [14]. The Kingdom of Saudi Arabia accounts for 59.4 percent of the 
purchases of pharmaceuticals products in the Gulf region. The market was estimated at USD 
5.75 billion in 2017 and poised to grow at CAGR 6.7 percent, expected to reach USD 8.46 
billion by 2023, according to a report published by Precision Business Insights. [15].     The 
Saudi Food and Drug Authority (SFDA) is the national regulatory body responsible for the 
regulation, registration, and approval of medicines in Saudi Arabia. It’s main objectives is to 
ensure the effectiveness, safety, and quality of medicines and it’s responsible for developing and 
implementing policies and procedures related to medicines. [16]. 
 
The need for a Conceptual Model and the future directions for policy 
  
A conceptual model could aid to build and identify priority medicines policy issues for Saudi 
Arabia. The aim to integrate the elements of health, medicines and public policy. Figure 1 
depicts the model as well as different stakeholders, including government, policy industry, 
academics, policy makers and consumers who could be involved in this process. Interaction 
between these stakeholders, as well as thematic document analysis, could lead to identifying 
some of the future health and medicines policy challenges in the country. 
 
It is important to see what above means for Saudi healthcare. What could be a growing set of 
challenges with regards to workforce, professional development, human and health services for 
the pharmaceutical and medicines sector. With the changing environment, how the policies 
related to medicines use and access will shape. There are challenges associated with the new 
biotechnological products, genomics and dose tailoring and how those will be resolved. The 
discussion above could lead to aid priority issues. The other pertinent issues could be medicines 
use in the society, accessibility of services and supporting health economic, 
pharmacoinformatics  and genomics research. 
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Fig 1: A conceptual model deriving priority medicines issues for Saudi Arabia 
 
